Navigation Links
Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

EO commented "I am delighted to report such positive results, which confirm the therapeutic and commercial potential of ACE393. This important outcome for ACE BioSciences validates our approach and preclinical work and keeps us on track to launch ACE393 in 2010. In September last year, we entered a collaborative development agreement with the US Naval Medical Research Center (NMRC) to progress ACE393 through Phase II clinical trials and we are about to initiate the first of these studies. These are exciting times for ACE BioSciences in a transformational year for the company."

72 healthy subjects participated in the trial which was undertaken at the Mediscis Phase I clinical unit in Poitiers, France. ACE BioSciences will continue to monitor those patients who received the vaccine at three monthly intervals to evaluate the longevity of the immune response. The full results of the study will be presented by Dr Michael Darsley, Chief Development Officer at ACE BioSciences at the Vaccines for Enteric Diseases Conference, held in Portugal on 25-27 April 2007.

TD is the most frequent health problem in travellers from industrialized countries visiting developing countries. Recent research undertaken by Beremans Ltd in the US and UK, indicates that an effective Campylobacter vaccine for Traveller's Diarrhoea might be purchased by over two million travellers per year and ACE BioSciences estimates that this annual global market would be worth _350 million. The company aims to claim a substantial share of the market by providing the first effective commercial Campylobacter vaccine that delivers good protection and low side effect risk.

Notes for Editors

About Travellers Diarrhoea

Campylobacter jejuni is a bacterium that is one of the main causes of travellers_ diarrhoea. In addition to the disruption it causes to business and holiday travellers, infection is a significant issue for the military and among the 140,000 US military perso
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
Post Your Comments:
(Date:7/1/2015)... 2015 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... inflammatory disease and neurologic disorders, announced today the results ... citrate, the Company,s lead compound. Results from the study ... can significantly inhibit the activation of inflammatory proteins in ... this compound in a Phase 1 clinical trial under ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3
... Amgen (Nasdaq: AMGN ), today announced the ... privately held biotechnology company based in Woburn, Mass., with ... a novel investigational oncolytic vaccine in Phase 3 clinical ... melanoma and head and neck cancer. The acquisition was ...
... , a leader in bioinformatics software and knowledge integration, ... license for Pathway Studio ® Enterprise system that ... MedScan® text processing technology for site-wide use. Pathway Studio ... pathways and develop mechanistic rationale for disease based on ...
Cached Medicine Technology:Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4Site-wide License for Ariadne's Pathway Studio Renewed by NCI 2
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will ... the Twin Cities on Saturday, August 1, at Spring Lake Park High School. , ... more than $1 million worth of goods and services including free food, health services, ...
(Date:7/1/2015)... ... 2015 , ... Scoliosis is a disorder in which the normally straight vertical line of the ... 3 percent of the population, or an estimated 6 to 9 million people. While it ... ages of 10 and 15. Most types of scoliosis are more common in girls than ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... compensation law has just published a top ten list they hope will guide ... Click here to read it now. , More than 450 ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only ... a national chief nursing officer recruitment for Capital Health in ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... Research ... Examination Kit (Peek) smartphone app to test eyesight was just as accurate as those ... School of Hygiene and Tropical Medicine is responsible for the development of the test, ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3
... a week, prevent painful flare-ups, study finds , , MONDAY, ... a safe, simple and inexpensive way of treating children ... disease, which affects 17 percent of school-age children, can ... in school. , Eczema-related itching can be so ...
... There is often disagreement between the professions of ... for coronary artery disease (CAD)and this can harm ... Deutsches rzteblatt International , an interdisciplinary team of ... answers to the question of when a bypass ...
... Survey of More than 420 Hospitals Show Major Medical ... by Several Hundred Dollars. WASHINGTON, April 27 ... out of every dollar spent on health care, one of the ... That,s according to a major new report to be released ...
... Have No-Cost Access to IAC for Electronic ClaimsJACKSONVILLE, ... premier health information network, today announced that Insurers ... the transmission of HIPAA compliant electronic claims. As ... IAC claims through the Availity(R) Health Information Network ...
... (April 27, 2009) In recognition of their distinguished ... at Harbor-UCLA Medical Center (LA BioMed) will honor four ... dinner celebration May 12 at Trump National Golf Club. ... Larry J. Shapiro, MD, and Mark A. Sperling, MD, ...
... technology teams up with ultraviolet-C light energy for 99% ... introduction of the Healthy Fan, which improves the indoor ... percent of airborne germs. The Healthy Fan maximizes air ... with a mounted air purifying medallion. It uses ...
Cached Medicine News:Health News:Diluted Bleach Baths Ease Kids' Eczema 2Health News:Study to Document Billions in Annual Health Care Savings From 'Group Purchasing Organizations' That Could Play Bigger Role in Obama Health Care Reform 2Health News:Study to Document Billions in Annual Health Care Savings From 'Group Purchasing Organizations' That Could Play Bigger Role in Obama Health Care Reform 3Health News:Insurers Administrative Corporation Joins the Availity Network 2Health News:Four legendary LA BioMed physician-researchers honored 2Health News:Four legendary LA BioMed physician-researchers honored 3Health News:Four legendary LA BioMed physician-researchers honored 4Health News:Four legendary LA BioMed physician-researchers honored 5Health News:Haledyne Debuts Air Sanitizing Technology for Healthier Home 2Health News:Haledyne Debuts Air Sanitizing Technology for Healthier Home 3
... OmniMD Medical Billing system allows a ... accounting. It is integrated with the ... The system interfaces with electronic clearinghouses ... With a set of reports, it ...
... CPNG3 single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... CPNG3 reagent provides a long shelf ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: